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Introduction
Acromegaly management is a significant challenge for
endocrinologists. The Acromegaly Consensus Group
developed several statements on the management of acro-
megaly and specifically on its medical treatment [1–3].
Acromegaly is a quite rare condition generally caused by a
growth hormone (GH)-secreting pituitary adenoma [4].
Delayed diagnosis leads to prevalent presentation of the
disease at the stage of macroadenoma (two-thirds of
patients) and frequent persistence of active disease after
surgery which remains in many patients the primary
treatment option [5]. However, active acromegaly is
potentially a life threatening condition due its severe sys-
temic complications [6, 7] Therefore, elevated GH and
insulin-like growth factor (IGF)-1 levels need to be strictly
controlled after failure of surgery with medical or radiation
treatments [8]. Furthermore, criteria for disease control
may not be fulfilled in a considerable proportion of patients
undergoing medical treatment with somatostatin receptor
ligands (SRLs) after unsuccessful surgery [9, 10].
Accordingly, some acromegaly patients require the
administration of GH antagonist Pegvisomant [11]. Peg-
visomant has been introduced in clinical practice more than
a decade ago as a medical therapy of acromegaly. How-
ever, specific guidelines for Pegvisomant use in acromeg-
aly are lacking. Therefore, the Italian Society of
Endocrinology constituted a task force with the objective
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of assessing the published literature and the clinical expe-
rience with Pegvisomant. This group involved endocri-
nologists recognized experts in the field of acromegaly
management and their understanding of the data reported
so far worldwide as well as their recommendations for
Pegvisomant use in clinical practice are presented here.
Biochemical and clinical results of Pegvisomant, indica-
tions, treatment modalities, combination therapies, safety
and regulatory and cost/efficacy issues were evaluated.
Evidences were graded with GRADE system [1–3, 12, 13]
based on the quality of evidence as very low quality (VLQ;
expert opinion with one or a small number of small
uncontrolled studies in support), low quality (LQ; large
series of small uncontrolled studies), moderate quality
(MQ; one or a small number of large uncontrolled studies
or meta-analyses), or high quality (HQ; controlled studies
or large series of large uncontrolled studies with suffi-
ciently long follow-up). Recommendations were defined
discretionary (DR) if based on VLQ-LQ evidence, or
strong (SR) if supported by MQ-HQ evidence.
What is Pegvisomant
Pegvisomant is a drug designed to block the GH receptor
(GHR) and, therefore, GH action. The discovery of this
GHR antagonist was made possible by the elucidation of
the structure–function relationship of GH and its receptor
[11, 14]. Growth hormone is a 22 kDa polypeptide with
191 amino acids, two disulphide bonds and four alpha
helices synthesized in the anterior pituitary and central to
regulation of growth and differentiation. It has many other
biological actions including enhancement of protein syn-
thesis, lipolysis and hyperglycemic effects. Although GH
may have direct effects on peripheral tissues most of its
growth promoting effects are mediated by IGF-1 [15–17].
Growth hormone has two distinct domains (sites one and
two) that interact with preformed GHR dimer on plasma
membrane triggering conformational changes required for
signaling [18]. The affinity of GH binding site one for GHR
is high whereas the affinity of site two is lower. After initial
high affinity binding at site one, subsequent binding at site
two produces functional receptor dimerization. After the
GH/GHR interaction, a series of intracellular signaling
systems is mobilized, resulting in the activation or inacti-
vation of genes responsible for GH action [19].
Pegvisomant is a GH analog with a single-aminoacid
substitution at position 120 that generates the antagonist.
Additional changes include amino acid substitutions within
binding site 1 and a further modification by the addition of
polyethylene glycol moieties [20]. The GHR antagonist
acts by failing to induce proper or functional GHR
dimerization. The pegylated [polyethylene glycol (PEG)]
counterpart Pegvisomant is generated by the conjugation of
GHR antagonist with four or five moieties of PEG 5000;
PEG molecule addition increases the size of the antagonist
and its serum half life from *30 min to more than 100 h,
by reducing renal clearance and intravascular proteolysis,
and reduces immunogenicity of the molecule [21]. Like
GH, the GHR antagonist has a relatively small size
(22 kDa), and is normally cleared via the kidneys and/or
GHR internalization [22].
Biochemical outcomes in trials and observational
registries
Circulating GH values are not useful as biochemical
marker of Pegvisomant effects in acromegaly both
because endogenous GH secretion may increase during
treatment due to negative feedback and, particularly, due
to cross-reactivity of GH with Pegvisomant in most GH
assays [21] (HQ). Therefore, GH should not be measured
in monitoring Pegvisomant treatment (SR). Normaliza-
tion of IGF-1 levels represents the main end point of
Pegvisomant treatment (HQ) [23, 24] although sudden
and remarkable GH increase during Pegvisomant therapy
could be a marker of tumor re-growth [25] (VLQ). Many
studies reported IGF-1 normalization or marked reduc-
tion in acromegaly patients treated with Pegvisomant
[26] (HQ). In addition, improvement in quality of life
was suggested even adding Pegvisomant in patients
already effectively controlled by SRLs [27] (VLQ).
However, reported effectiveness of Pegvisomant varied
widely depending on the type of study (clinical trial vs.
observational) as it happens with other medical therapies
in acromegaly [3] (MQ). Indeed, serum IGF-1 levels
normalized in more than 90 % of patients particularly in
initial clinical trials [28–32], while the control rate was
lower in studies performed in the clinical setting and
based on the retrospective analysis of disease-specific
databases [33–39] (Table 1). Inadequate dose titration,
poor compliance to daily injections, suboptimal selection
of patients and technical problems related to IGF-1 assay
could justify a lower than expected efficacy in ‘‘real
life’’ conditions (VLQ), since the existence of a true
‘‘biochemical resistance’’ to Pegvisomant, as observed
with SRLs [40], has not been clearly documented yet
(VLQ). Effectiveness of Pegvisomant may be inversely
correlated to baseline IGF-1 levels and starting dose
should be higher and dose titration more rapid in patients
with a worse endocrine profile (VLQ) [26, 41]. Better
efficacy of Pegvisomant was associated with male gen-
der, leanness, lower baseline GH and/or IGF-1 levels,
previous irradiation, and related to treatment duration
and appropriate dose titration (LQ) [37, 38, 41]. The role
1018 J Endocrinol Invest (2014) 37:1017–1030
123
of d3GHR polymorphism, which could modify receptor
sensitivity to GH [42], in response to Pegvisomant is still
controversial (VLQ) [43–45]. Availability of validated
assays is crucial for monitoring appropriately effective-
ness of treatment and dose titration (SR). For this reason,
IGF-1 values should be measured with the same method
over time in each patient (SR). At present, considerable
differences exist among available assays, due to lack of
standardization, use of different types of antibodies and
interference of binding proteins (MQ) [46]. Moreover,
specific age-related normative intervals are rarely
obtained, as recommended by available general guide-
lines [10], in local populations by centralized laboratories
(LQ). Finally, given the within-individual biological
variation of IGF-1 assays caution should be also used in
interpreting values close to reference limits even if
obtained with the same method [47, 48] (DR).
Peripheral and tissue effects of Pegvisomant
Treatment with Pegvisomant improves clinical syndrome
of acromegaly in a high percentage of patients (HQ),
positively impacts glucose metabolism (MQ), quality of
life (MQ) and cardiovascular and skeletal complications
(MQ) [49] (Table 2).
Table 1 Summary of biochemical results with Pegvisomant treatment in clinical trials and observational/retrospective studies in acromegaly









IGF-1 normalization 3 100 30–80 mg/weekly 6 weeks
3 100 10–20 mg/day 3 months
Trainer et al. [29] Dose-related
efficacy
109 10 placebo 33 months
38 10 mg/day 3 months
75 15 mg/day 3 months
82 20 mg/day 3 months
van der Lely et al. [30] IGF-1 normalization 90 97 – 12 months
62 92 – 18 months
Drake et al. [31] IGF-1 normalization 7 100 20 mg/day (median; range 15-40) 24 months
Barkan et al. [32] IGF-1 normalization 49 78 16 mg/day (mean; range 5-40) 8 months
Colao et al. [26] IGF-1 normalization 12 75 25 mg/day (median; range 10-40) 12 months
Observational or retrospective studies:
Schreiber et al. [33] IGF-1 normalization 147 64 16.5 mg/day (mean; range 10-50) 6 months
102 71 12 months
39 76 24 months
Higham et al. [34] IGF-1 normalization 11 95 15 mg/day (median; range 10-60) 91 months
Trainer [35] IGF-1 normalization 792 62 15 mg/day (median in controlled
patients)
60 months
16 mg/day (median in not controlled
patients)
Buchfelder et al. [36] IGF-1 normalization 273 56 15 mg/day (median) 6 months
202 71 24 months
133 71 36 months
71 65 48 months
24 58 60 months
Marazuela et al. [37] IGF-1 normalization 44 84 17 ± 7 mg/day in men16 ± 8 mg/day in
women
23 months (mean)




28 46 9.6 mg/day (mean) 3 months
59 6 months
van der Lely et al. [39] Safety and efficacy 1288 63 18 mg/day (mean in controlled patients)
20 mg/day (mean in uncontrolled
patients)
43 months (mean)
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Glucose and lipid metabolism
In acromegaly, abnormal glucose tolerance, insulin resis-
tance, hyperinsulinemia and diabetes mellitus are fre-
quently observed [50] (HQ). Medical treatment of
acromegaly may variably influence glucose metabolism. It
is known that SRLs inhibit insulin secretion, inducing a
possibly negative impact on glucose homeostasis (MQ)
[51], whereas Pegvisomant improves insulin sensitivity
likely by ameliorating IGF-1 excess and its effect on
insulin resistance (MQ) [33, 52–57]. Several studies dem-
onstrated that Pegvisomant monotherapy induced a
significant decrease in fasting glucose levels and HbA1c
[33, 52–54, 58] also in patients with diabetes mellitus and
impaired glucose tolerance (MQ). A positive impact of
Pegvisomant on peripheral insulin sensitivity was also
demonstrated [52, 55–57] (MQ). However, a substantial
proportion of patients included in these studies were
resistant to SRLs; therefore, improved glucose metabolism
could derive from better biochemical control and/or to
removed inhibitory effect of SRLs on insulin secretion [58]
(VLQ). Variable results were observed on lipid metabolism
after Pegvisomant. An increase in total and LDL choles-
terol with unchanged triglyceride levels and a significant
decline in lipoprotein (a) levels was observed [59, 60],
whereas other authors [24, 61] reported that lipid profile
did not change during Pegvisomant therapy (LQ).
Cardiovascular and skeletal complications
Acromegaly is associated with a specific cardiomyopathy,
characterized by biventricular hypertrophy and compli-
cated by initial diastolic dysfunction and late systolic
dysfunction, potentially leading to heart failure (HQ) [62].
Furthermore, systemic arterial hypertension, frequently
associated with the disease, contributes to worsening
acromegalic cardiomyopathy [62]. Long-term (18 months)
treatment with Pegvisomant induced a significant reduction
of cardiac mass and significant improvement of diastolic
and systolic function in patients with acromegaly mostly
resistant to SRLs (LQ) [63]. Treatment with Pegvisomant
could also exert beneficial effects on rhythm disorders and
hyperkinetic syndrome (LQ) [64]. Moreover, 12 months of
Pegvisomant therapy were associated with improved blood
pressure, particularly of diastolic values, in hypertensive
patients [24, 61] (LQ). IGF-I normalization significantly
lowered predicted cardiovascular risk, calculated with the
Framingham risk score [61] (LQ). On Pegvisomant slight
reduction of carotid arteries wall thickness and significant
improvement of brachial arteries vascular function in
patients with acromegaly resistant to SRLs were reported
(VLQ) [65].
Growth hormone and IGF-I play a significant role in the
regulation of bone metabolism [66, 67] (HQ). Acromegaly
increases risk of vertebral fractures not necessarily asso-
ciated with reduced bone mass (MQ) [68–70] but with
increased bone turn-over which normalized during
6 months of Pegvisomant treatment [71, 72] (LQ). Long-
term treatment with Pegvisomant also induced a significant
increase of bone mineral density in active acromegaly (LQ)
[73]. Although Pegvisomant use was weakly associated
with an increased rate of fractures this has been attributed
to global increased severity of the disease in treated
patients [70] (LQ).




Fasting glucose levels * [52–54]
Glucose tolerance * [53, 58]
HbA1c % * [33, 53]
Insulin sensitivity * [52, 55–57]
HOMA index [52, 55]
Lipid metabolism
Total cholesterol / = [59, 60] / [26, 61]
LDL cholesterol / = [59, 60] / [26, 61]
Triglyceride = [59, 60] / [26, 61]
Lipoprotein (a) * [59, 60]
Cardiovascular complications
Cardiac mass * [63]
Systolic and diastolic function * [63]
Rhythm disturbances * [64]
Blood pressure * [26, 61]
Framingham risk score * [61]
Carotid arteries wall thickness [65]
Brachial arteries vascular function * [65]
Skeletal complications
Bone turn-over * [71, 72]
BMD * [73]
* Denote significant change
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Indications
Pegvisomant is traditionally indicated for treatment of
acromegaly patients with inadequate response to pituitary
adenomectomy or radiation therapy, or for those intol-
erant or resistant to SRLs (HQ). However, a clear-cut
definition of resistance to SRLs is missing (VLQ) [74].
In fact, during SRL therapy biochemical control is
defined as random basal GH lower than 1 mcg/liter and
IGF-1 levels below the upper limit of normal range for
age (MQ) [3]. Using these strict criteria [10] normali-
zation of biochemical activity in unselected patients with
acromegaly after long-term ([6–12 months) treatment
with maximal SRL doses occurs approximately in
25–50 % of cases [3, 75–77] (MQ). Non-responders to
SRL therapy (minimal effect on GH and IGF-I levels
and on tumor shrinkage) should be switched to Pegvi-
somant (SR). In partial responders to SRLs, Pegvisomant
monotherapy or combination therapy with Pegvisomant
and SRL should be considered (DR). Tumor shrinkage
quite frequently (around 50 % of treated patients) occurs
during therapy with SRLs often but not necessarily
together with biochemical normalization [78–80] (MQ).
Interestingly, in patients with acromegaly and McCune
Albright syndrome surgery and even radiation therapy
often can not be performed [81] and SRLs have very
low chances to be effective [81] (LQ). In these patients,
Pegvisomant can be considered as primary treatment
(DR). Moreover, primary post-surgical medical treatment
with Pegvisomant should be considered in patients
already proven to be resistant to SRLs as those who
underwent a sufficiently long ([3–6 months) trial of pre-
surgical SRL treatment which demonstrated to be inef-
fective in controlling GH and IGF-1 (unless a [ 75 %
surgical debulking is achieved [82]) (DR). Primary post-
surgical Pegvisomant treatment can be considered in
patients after irradiation in whom elevated IGF-1 levels
may persist for long time but likelihood of tumor
regrowth is modest [1] (DR) and in patients with poorly
controlled diabetes mellitus in whom SRLs may poten-
tially worsen glucose metabolism [51–54] (DR).
Treatment modalities
Pegvisomant is administered by subcutaneous injections.
Ten, 15, and 20 mg per vial are available dosages. Ini-
tially, treatment regimens contemplated a 40–80 mg
loading dose. In clinical practice this procedure has not
proven to be useful and has been abandoned (LQ) [23].
Daily administration is the most effective because it
achieves higher serum Pegvisomant concentrations with a
lower dose of drug (MQ) [29, 83]. The target of therapy
is to achieve serum IGF-I in the middle of age-related
reference range (MQ) [11]. Starting dose is usually
10 mg/day and maximum maintenance dose which cur-
rently can be administered based on regulatory indica-
tions is 30 mg daily (LQ) [84]. For patients who require
a dose [20 mg daily, Pegvisomant treatment is more
inconvenient due to daily multiple injections (VLQ) [85].
After treatment start, serum IGF-I levels fall within
2 weeks and then reach a plateau after 4 weeks (HQ)
[29]. Consequently, it is suggested to measure IGF-I 4 to
6 weeks after beginning treatment and after every change
of dose until biochemical control is reached (DR). Once
serum IGF-I levels are normalized, they should be
monitored every 3–6 months [38] since Pegvisomant
dose may require up- or down-titration in the same
individual during treatment (DR) [3].
Combination therapies
Dopamine agonists
Cabergoline, a dopamine receptor agonist, has limited
activity when used as monotherapy in acromegaly (MQ)
[86, 87]. However, its combination with SRLs was shown
to be effective in some patients (LQ) [86]. Few data are
available regarding the combination of cabergoline and
Pegvisomant. However, it was reported that addition of
Pegvisomant to cabergoline as well as of cabergoline to
Pegvisomant may result in improved IGF-1 control (LQ)
[88, 89]. A better response was associated with baseline
IGF-1 levels not higher than 160 % of ULN. No correlation
was found with baseline prolactin levels. The combined
treatment was well tolerated and safe (LQ).
Somatostatin receptor ligands
When compared with monotherapy, combination treat-
ment with SRLs may require a lower dose (even in only
1 weekly administration) of Pegvisomant to obtain sim-
ilar efficacy (MQ) (Table 3) [90–93]. This is due to
different mechanisms, including elevation of serum
Pegvisomant levels [93], reduced insulin concentration in
the portal vein, which decreases the number of available
liver GH receptors [94] and reduced endogenous GH
levels (LQ). In all reported trials, combination treatment
was generally well tolerated (LQ). However, transient
liver function test abnormalities were observed in a
variable percentage of cases (11–38 %), apparently
higher when compared with monotherapy. Significant
tumor shrinkage during combined treatment was
observed in 13–19 % of patients [95]. Glucose metabo-
lism was not substantially affected [96].
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General and tumor growth safety
General safety
In clinical trials, Pegvisomant has been shown to be
generally safe and well tolerated [29, 30] (HQ). In a
global non-interventional surveillance study (1,288 sub-
jects, mean duration 3.7 years) Pegvisomant-related
adverse events (AE) (changes in tumor size, increase in
liver enzymes, and injection site reactions) were recorded
in 9.6 % of subjects [39]. In all studies, mortality was
not related to Pegvisomant use (MQ). Injection-site
reactions were initially reported with a frequency up to
11 % and were generally mild, erythematous, self-limited
and did not require treatment [29, 30]. Lipodistrophy
during Pegvisomant therapy was sporadically reported
likely due to local lypolitic GH inhibition (LQ). Frequent
rotation of injection sites could prevent local reactions
and patients should be carefully monitored and trained
[97, 98] (SR). Surveillance studies [33, 98] reported an
elevation of liver transaminase levels [ 3 times ULN in
about 5–8 % of patients mainly previously treated with
SRLs. Transaminase level elevations during Pegvisomant
treatment were often mild and transient, did not appear
to be dose-related (idiosyncratic drug toxicity?) and
occurred within the first year of treatment (MQ). Rare
cases of drug-induced hepatitis (but not liver failure)
were reported (VLQ) [99]. When Pegvisomant was
combined with SRLs, transient liver enzyme elevations
seemed to be 2–3 times more frequent (MQ) [33, 39, 82,
99–103]. Controversial is the correlation between diabe-
tes mellitus and elevated transaminase levels (VLQ) [33,
92, 99, 101]. A common polymorphism found in Gil-
bert’s syndrome was associated with Pegvisomant-
induced liver injury [104]. Biliary complications may
arise from restitution to normal of gallbladder motility
after cessation of SRL treatment [10]. We recommend
not to start Pegvisomant if there is a liver dysfunction
(SR). Liver function should be evaluated monthly for at
least 6 months after initiating therapy, quarterly for next
6 months, and then semi-annually (SR). If transaminases
increase [5 times ULN or [3 times ULN with increased
serum bilirubin Pegvisomant must be discontinued (SR).
If transaminases increase \ 3 times ULN without signs
or symptoms of liver failure Pegvisomant could be
continued (DR), but they must be monitored weekly
(SR) [24, 29, 33]. Since Pegvisomant may improve
glucose tolerance, glucose levels should be monitored
particularly in first months of treatment and anti-diabetic
drugs adjusted if necessary (DR) [30, 33].
Tumor growth safety
Only 1 out of 43 subjects treated with Pegvisomant for
29 months and monitored for 58 months, showed an
increase in pituitary tumor volume [105]. In the German
Pegvisomant Observational Study [106] in 18 out of 307
(5.9 %) patients treated with Pegvisomant for an average of
86 weeks tumor size increased; however, after centralized
image re-evaluation, tumor progression was confirmed in
only eight patients (3 %). Among 61 patients observed by
Buhk et al. [107], in 3 (4.9 %) increased tumor vol-
ume [25 % during the first year of therapy was reported.
Marazuela et al. [37] observed significant increased tumor
size in 6.7 % of subjects (5 of 75), followed for
29 ± 20 months; absence of previous irradiation and
shorter duration of pre-Pegvisomant SRL therapy were
associated with increased risk of growth (LQ). In the global
surveillance study [39] incidence of increased pituitary
tumor size was 7.2 % (67 of 936) in the local MRI reading,
while again it was only 3.2 % (45 of 936) in the central
reading. Thus, a careful serial evaluation of all available
images is necessary to avoid misinterpretations (SR) [39,
106]. Therefore, tumor growth, observed more frequently
during the first year of treatment, may prevalently reflect
the disease natural history [24, 30] or the consequence of
SRL discontinuation [106]. On the contrary, irradiation
seems to be associated with a reduction in tumor size [24,
105, 108]. All patients treated with Pegvisomant should
undergo regular sellar MRI to screen for potential tumor
growth (SR). A more intensive MRI follow-up protocol
should be followed in non-irradiated patients (DR).
Regulatory and cost/efficacy issues
Regulatory issues
Pegvisomant was licensed for the treatment of acromegaly
in 2002 by EMA (EU, European Medicines Agency) and in
2003 by FDA (US, Food and Drug Administration). Label
indications in EU limit use of Pegvisomant to patients with
acromegaly with inadequate response to surgery and/or
radiation therapy and in whom medical treatment with
SRLs did not normalize IGF-I or was not tolerated (third
line therapy). Label indications in US indicate Pegvisomant
in acromegaly patients with inadequate response to surgery
and/or radiation therapy and/or other medical therapies, or
for whom these therapies are not appropriate (first/second
line therapy in specific cases) better reflecting available
guidelines (MQ) [1–3]. Pegvisomant should be prescribed
J Endocrinol Invest (2014) 37:1017–1030 1023
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by doctors with expertise in acromegaly management
(MQ). National and regional regulatory agencies provide
largely variable criteria to allow centers for prescription
(VLQ). First injection of Pegvisomant should be done
under close medical supervision (SR) and specific warnings
about systemic hypersensitivity reactions were recently
added in the package leaflet. Injections less frequently than
daily normalize IGF-I levels in some patients [108] and in
Acrostudy [39] 12 % of clinicians did not use daily
injections (VLQ). Combination therapy Pegviso-
mant ? SRLs is not recommended by EMA though the
Agency recognized the interest for the complementary
actions of these drugs. Pegvisomant in combination therapy
is considered an ‘‘off-label’’ use by some local regulatory
agencies. Pegvisomant should not be used during preg-
nancy unless clearly necessary according to EMA and FDA
(MQ) (pregnancy class B). In fact, there are only few
reports about its safety in pregnancy [109].
Cost/efficacy analysis
Pegvisomant is an effective but expensive drug (MQ). Cer-
tainly, the direct costs of neurosurgery, dopaminergic agents,
SRLs and radiotherapy are lower than lifelong Pegvisomant
treatment, but standard therapies do not provide biochemical
normalization in some patients (HQ). On the other hand,
control of disease is associated with normalized mortality
rate and improvement of comorbidities (HQ) [1–3]. In
addition, burden of direct and indirect (associated comor-
bidities and loss of working days) costs is higher in patients
with acromegaly not controlled by standard therapies (MQ)
[110, 111]. Therefore, if Pegvisomant is prescribed accord-
ing to licensed use it may be cost-effective considering rel-
ative rarity of acromegaly (MQ). Nevertheless, according to
a pharmacoeconomic model [112] the best cost-effective-
ness ratio could be reached with Pegvisomant price reduced
by about one-third (VLQ).
Summary of recommendations
Place of Pegvisomant in guidelines
Primary treatment
Pegvisomant cannot be recommended as primary treatment
of the general acromegaly population (SR). In fact, surgery
(performed by an experienced neurosurgeon) remains the
primary treatment option in patients with acromegaly with
totally resectable tumor (SR). Moreover, SRLs are primary
medical treatment if surgery is contraindicated, not
accepted by the patient or in case of poor likelihood of total
surgical resection (SR). When surgery and radiation
therapy cannot be performed and SRL are unlikely to be, or
may not be, effective as in patients with acromegaly and
McCune Albright syndrome or empty sella [113] Pegvi-
somant could be considered as primary treatment option
(DR).
First-line (post-surgery) pharmacologic treatment
SRLs are primary first-line therapy after surgery (SR).
Primary postsurgical therapy with cabergoline may be
considered particularly in patients with relatively mild
disease [114] (DR). There are at least three circumstances
in which primary postsurgical medical treatment with
Pegvisomant could be considered (DR): (1) patients who
underwent a sufficiently long ([3–6 months) trial of pre-
surgical SRL treatment [3] that was ineffective in con-
trolling GH and IGF-1 and in whom mass effect of residual
tumor is not an issue; (2) patients with residual tumor in
whom radiation treatment is given as second option: in
fact, after radiation elevated IGF-1 levels may persist for
long time but likelihood of tumor regrowth is modest [1];
(3) patients with poorly controlled diabetes mellitus in
whom SRL treatment may potentially worsen glucose
metabolism [51–54].
Second-line pharmacologic treatment
Partial (GH and IGF-I decreased but not normalized) or no
response (minimal changes in GH and IGF-1) to SRLs may
be observed (HQ) [3]. Patients with no response after an
adequately long (6–12 months) period of treatment with
maximal doses of SRL should be switched to Pegvisomant
monotherapy (SR). If biochemical control is not achieved
Pegvisomant dose should be increased (SR) and/or com-
bination treatment with dopamine agonists should be given
(DR). In patients who do not achieve biochemical control
of the disease [7] but have documented partial response to
SRLs ([50 % reduction of GH and IGF-1 vs. baseline and/
or tumor shrinkage [20 %) either switching to Pegviso-
mant monotherapy or combination therapy Pegviso-
mant ? SRL should be considered (DR). If
SRL ? Pegvisomant combination is not effective a possi-
ble alternative could be association of Pegvisomant with
dopamine agonists (DR) [3] (Fig. 1). Patients seldom do
not tolerate SRL treatment for gastrointestinal side effects
(LQ) [115]: these subjects should be switched to Pegvi-
somant monotherapy regardless biochemical efficacy of
SRL (taking into account potential mass effect) (SR).
Dose, efficacy and safety monitoring
Individual optimal dose of Pegvisomant may vary
according to anthropometric and genetic characteristics
1024 J Endocrinol Invest (2014) 37:1017–1030
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(VLQ). Recommended starting dose is 10 mg/day s.c.
(DR). An initial load dose of Pegvisomant is not recom-
mended (DR). Doses of Pegvisomant exceeding 30 mg/day
are not recommended although in biochemically and clin-
ically persistently active disease with no other treatment
choice a further dose increase to 40 mg/day could be
considered (DR).
Growth hormone should not be measured to assess
effects of Pegvisomant (SR). Goal of Pegvisomant treat-
ment is to normalize circulating IGF-1 levels (SR). Bio-
chemical effects of Pegvisomant should be checked in
laboratories with experience in IGF-1 measurement which
give reference values divided by decade of age (SR).
Patients with deranged glucose homeostasis on SRLs
should be switched to Pegvisomant (DR). SRL treatment is
known to counteract myocardial hypertrophy in patients
with acromegaly [116] (HQ). Pegvisomant was also asso-
ciated with positive cardiovascular effects and acromegaly
cardiopathy does not contraindicate Pegvisomant (SR).
Pegvisomant is the only treatment which was shown to
normalize bone turnover in acromegaly [71] and prevalent
vertebral fractures do not contraindicate Pegvisomant (DR).
Patients with known liver dysfunction should not be
initiated with Pegvisomant (SR). Liver function should be
evaluated periodically during therapy (SR). Injection-site
reactions, such as lipodystrophy or lipohypertrophy may
rarely occur and frequent rotation of injection sites is rec-
ommended (SR). Unlike SRLs [78–80] Pegvisomant
treatment does not target tumor (HQ). Therefore, regular
MRI monitoring is required (SR).
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